UBS Group
ENVB icon

UBS Group’s Enveric Biosciences ENVB Stock Holding History

UBS Group’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277 Sell
201
-3,411
-94% -$8.19K ﹤0.01% 9947
2026
Q1 		$7.01K Buy
3,612
+717
+25% +$1.96K ﹤0.01% 8633
2025
Q4 		$10.5K Sell
2,895
-5,883
-67% -$38.3K ﹤0.01% 8209
2025
Q3 		$67.3K Buy
8,778
+6,500
+285% +$85.2K ﹤0.01% 7364
2025
Q2 		$33.1K Sell
2,278
-1,285
-36% -$19.5K ﹤0.01% 8094
2025
Q1 		$59.4K Buy
3,563
+3,127
+717% +$108K ﹤0.01% 7446
2024
Q4 		$28.1K Buy
436
+432
+10,800% +$31.3K ﹤0.01% 7657
2024
Q3 		$346 Sell
4
-238
-98% -$21.9K ﹤0.01% 8989
2024
Q2 		$27.3K Buy
242
+214
+764% +$32.3K ﹤0.01% 7114
2024
Q1 		$4.98K Buy
+28
New +$5.4K ﹤0.01% 7570
2023
Q4 		– Sell
-2
Closed -$614 – 9103
2023
Q3 		$740 Buy
+2
New +$901 ﹤0.01% 8306
2023
Q2 		– Sell
-30
Closed -$14.6K – 8420
2023
Q1 		$8.85K Buy
30
+17
+131% +$7.15K ﹤0.01% 7690
2022
Q4 		$5K Sell
13
-16
-55% -$8.85K ﹤0.01% 9235
2022
Q3 		$22K Buy
+29
New +$36.5K ﹤0.01% 7253
2022
Q2 		– Sell
-11
Closed -$23.4K – 10457
2022
Q1 		$32K Buy
11
+9
+450% +$39.8K ﹤0.01% 6918
2021
Q4 		$13K Buy
+2
New +$28.1K ﹤0.01% 8443
2021
Q3 		– Sell
-7
Closed -$136K – 9174
2021
Q2 		$160K Buy
7
+4
+133% +$85.7K ﹤0.01% 5520
2021
Q1 		$97K Buy
+3
New +$105K ﹤0.01% 5989
2020
Q3 		– Hold
0
– -$2K – 8086
2020
Q2 		– Hold
0
– – – 7624
2020
Q1 		– Hold
0
– – – 7284
2019
Q4 		– Hold
0
– – – 8173
2019
Q3 		– Hold
0
– – – 7210
2019
Q2 		– Hold
0
– – – 7935
2019
Q1 		– Hold
0
– – – 6384
2018
Q4 		– Hold
0
– – – 7625
2018
Q3 		– Hold
0
– – – 6662
2018
Q2 		– Hold
0
– – – 7187
2018
Q1 		– Hold
0
– – – 7633
2017
Q4 		– Hold
0
– – – 7703

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group's ENVB Position: Q2 2026 in Review

UBS Group reduced its Enveric Biosciences (ENVB) stake by 94% in Q2 2026, selling an estimated $8.19K and leaving 201 shares worth $277. The position accounts for ﹤0.01% of the portfolio, ranked #9947.

UBS Group first reported a position in ENVB in Q1 2021 and has held it in 18 quarters since. The position peaked at $160K in Q2 2021. 15 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

  • UBS Group held 201 shares of Enveric Biosciences worth $277 as of Q2 2026.
  • UBS Group sold 3,411 Enveric Biosciences shares in Q2 2026, an estimated $8.19K.
  • Enveric Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9947 holding.
  • UBS Group first reported a position in Enveric Biosciences in Q1 2021 and has held it in 18 quarters since.
  • UBS Group's Enveric Biosciences position peaked at $160K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.